secwatch.observer — SEC 8-K summary
======================================

Issuer:     WEST PHARMACEUTICAL SERVICES INC (WST)
CIK:        0000105770
Form:       8-K
Filed at:   2026-04-23T23:59:59+00:00
Accession:  0000105770-26-000047
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

West Pharma Q1 beats: revenue up 21%, adj. EPS up 47%; raises FY26 guidance
---------------------------------------------------------------------------

- Net sales of $844.9M (+21% reported, +15.3% organic); GAAP EPS $1.92 (+56%), adjusted EPS $2.13 (+47%)
- High-Value Components revenue $409.3M (+29.6%); HVP Delivery Devices $123.6M (+29.0%); West Vantage $150.6M (+11.6%)
- Raised FY26 net sales guidance to $3.295-3.350B (prev $3.215-3.275B) and adj. EPS to $8.40-8.75 (prev $7.85-8.20)
- Repurchased 1.2M shares for $297.6M at avg $243.57/share under February 2026 buyback program
- Q2 2026 guidance introduced: net sales $830-850M, adj. EPS $2.05-2.12; SmartDose sale to AbbVie expected mid-year

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/105770/000010577026000047/0000105770-26-000047-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/105770/000010577026000047/wst-20260423.htm
  HTML page:      https://secwatch.observer/filing/0000105770-26-000047

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer